Characterization of Oral Gut-Selective vs. Systemic JAK Inhibitors in the Mouse Oxazalone Colitis Model, New Webinar Hosted by Xtalks
Autoimmune diseases such as ulcerative colitis require chronic treatment that often causes systemic immunosuppression, increasing long-term cancer and infection risk. Reducing systemic side effects with localized treatment would greatly benefit patients.
TORONTO, November 27, 2018 (Newswire.com) - This live webinar upcoming on Tuesday, Dec. 18, 2018, at 12:30 p.m. EST will explore the spatial characterization of oral gut-selective versus systemically available JAK inhibitors in the mouse oxazalone model of ulcerative colitis using the GeoMx™ Digital Spatial Profiler (DSP) from NanoString®.
Preclinical in vivo characterization of localized drug inhibition can be challenging. Traditional analysis of gut-selective JAK inhibitors, utilizing whole tissue homogenization, is not able to resolve cell type-specific inhibition. GeoMx allowed for custom, multiplexed and highly quantitative spatial sampling of mouse colons. Importantly, the platform’s single-cell masking capabilities mean that infiltrating immune cells in the intestinal mucosa can be sampled independently of non-immune tissue. This enabled the characterization of the spatial heterogeneity of the preclinical mouse model and to discriminate the effects of treatments on distinct cell types. Characterizing models up front can shorten time spent on model development, identify complex effects of target inhibition and better characterize cell types involved with disease progression.
John featured speaker Whitney Krey-Epstein, Scientist, in vitro Pharmacology, at Theravance Biopharma US, as she discusses how measuring inhibition in multiple cell types in spatially distinct layers of a mouse colon will show that an oral gut-selective JAK inhibitor has similar inhibition compared to a systemic drug, but with markedly lower systemic exposure.
For more information about this complimentary webinar, visit Characterization of Oral Gut-Selective vs. Systemic JAK Inhibitors in the Mouse Oxazalone Colitis Model.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.
Contact:
Nima Rajan
Tel: +1 (416) 977-6555 ext 352
Email: nrajan@xtalks.com
Source: Xtalks
Related Media
